Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
1. Pfizer will acquire Metsera for up to $7.3 billion. 2. Metsera's obesity drug MET-097i shows promising weight loss results. 3. The drug may outperform current treatments in terms of tolerability. 4. Analysts expect Metsera's candidates could generate $5 billion annually. 5. Further data is pending from ongoing trials for additional insights.